Answers are grounded in this paper and cite their sources.
Retrospective cohort study shows apolipoprotein a-i level impacts all-cause mortality in CHF, indicating its potential as a prognostic marker.
The present study aimed to explore the predictive value and prognosis of apolipoprotein A-I (ApoA-I) in chronic heart failure (CHF) patients. We recruited 4442 patients with CHF who were admitted to The First Affiliated Hospital of Xinjiang University Medical University with a period of ten years from July 2012, and the mean follow-up time was 22.75 months. The endpoints were defined as all-cause mortality (ACM), the patients divided into low and high ApoA-I groups according to the optimal cutoff value of the ROC curve from finally analyzed HF patients. In the whole follow-up periods, multivariate Cox regression analysis showed that total CHF patients in low ApoA-I groups had significantly increased risk of ACM as compared with patients in the high ApoA-I group (hazard ratio [HR]=0.702, 95%confidence interval [CI]: 0.603-0.817, P <0.001). This trend was consistent in patients with heart failure with mid-range (HFmrEF) (HR = 0.443, 95% CI: 0.298-0.658, P <0.001) and heart failure with preserved ejection fraction (HFpEF) (HR = 0.704, 95% CI: 0.539-0.919, P = 0.010), but not in heart failure with reduced ejection fraction (HFrEF) (HR = 0.806, 95% CI: 0.582-1.116, P = 0.194). The Apolipoprotein A-I concentrations significantly associated with ACM of CHF especially in HFmrEF and HFpEF.
No takes yet. Share an insight, caveat, or question.
He et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: